📢 New study from out lab published in @CellSystemsCP: REPROcode — a combinatorial single-cell screening platform to discover the transcription-factor (TF) recipes that reprogram immune cells.
Read it here: https://t.co/mz9QrKgaeS
📢 New in @ImmunityCP: We have mapped the transcription factor “routes” that program two dendritic cell subsets opening paths for personalized #cancer#immunotherapy.
Read it here: https://t.co/u4j9xoVhEL
Here is a summary of what we discovered 🧵:
Illustration by @azuravesta
Our study in one image!
It shows a cancer immunotherapy modality by reprogramming tumor cells within tumor microenvironment to dendritic cells that glow as a light bulb in the dark symbolizing the dawn of a new class of cancer treatments.
Illustration by the talented @joana_gcc
.@ervin_ascic, @nmalavika05, and colleagues at the @CellReproLab reprogrammed tumor cells in vivo by adenoviral delivery of the transcription factors PU.1, IRF8, and BATF3, which enabled them to present antigens as type 1 conventional dendritic cells. 🧫
https://t.co/Z7ob6YnYjL
Thrilled to share our latest research published in @ScienceMagazine! 🎉
A big shout-out to the lead author @ervin_ascic, the incredible team @CellReproLab, @AsgardThx & all our collaborators for making this possible. Excited about the impact this work will have on the field!
1/23 We are excited to announce that our most recent study “In vivo dendritic cell reprogramming for cancer immunotherapy” was published in @ScienceMagazine.
https://t.co/yPDqKmpGnn
Here is a summary of what we discovered!
🎉 Congratulations to @luisfholiveira, PhD student in the lab, for the #ISSCR2024 Exceptional Scientific Poster Presentation Award!
His poster “Transcription Factor Blueprints Underlying #Dendritic Cell Diversity” was selected amongst over 1400!
#Immunity#Reprogramming
🌟1/7 Check out our new pre-print “A cancer #immunotherapy modality based on dendritic cell #reprogramming in vivo”, where we reprogram #tumor cells in situ to efficiently present antigens as type 1 conventional dendritic cells (cDC1s). How effective is it?
✨ Catch the poster presentations by our lab members @halitzki, @nejcarh, @luisfholiveira and @nmalavika05 at #ISSCR2024!
📌 Check the flyer below for all information regarding times and poster numbers.
See you at the CCH – Congress Center Hamburg! ☺️
✨ Excited for #ISSCR2024!
Don't miss the concurrent session on "Novel approaches to program and perturb cell fate" featuring presentations by Filipe and @CamilaVazquezE.
📌 Join us on July 12, 13:30-15:00 at CCH – Congress Center Hamburg, Hall 4!
🌲 Had a blast on the hike with @AsgardThx ! Nature, bonding, and brainstorming – lab activities redefined!
💡Reflecting on 2023, setting ambitious goals for 2024!
#TeamBuilding#LabLife#HikingFun
🎄✨Another heartwarming A12 Christmas dinner in the books! Grateful for the cherished tradition on our floor—laughter, love, and festive vibes filled the room. ❤️🎅 Until next year, #A12Family! #MemorableMoments#ChristmasJoy
📢 Bridging direct cell reprogramming and cancer immunotherapy: our new study on reprogramming cancer cells into antigen-presenting dendritic cells (Tumor-APCs) is out @SciImmunology. Read on https://t.co/8DcO9lwgPh to know more. #ScienceResearch#reprogramming
We would like to introduce Carl 1st to the world - the first cured animal with #reprogramming in Lund! An outcome of the REPRINT European consortium to establish proof-of-principle for new cancer immunotherapy based on in-vivo reprogramming of tumor cells to #dendritic cells🎉
We are recruiting, big time! Join us if you are passionate about cell #reprogramming, #immunology, and the development of new #immunotherapy strategies! Also an opportunity to take the first steps on #innovation!
It was an exciting kick-off meeting with the consortium partners of the Eurostars REPRINT project. We are paving the way for an entirely new cancer immunotherapy platform based on cellular reprogramming!
#REPRINT#cellularreprogramming#cancerimmunotherapy